What Daiichi Sankyo UK does

Daiichi Sankyo UK Ltd is a privately held UK pharmaceutical affiliate of Japan's Daiichi Sankyo Co. Ltd., headquartered at Uxbridge Business Park and operating since its 2006 founding. The company develops, registers, and supplies prescription medicines to the NHS in two therapeutic areas: cardiovascular disease (hypertension treatments Olmetec, Olmetec Plus, Sevikar and Sevikar HCT; anticoagulant Lixiana/edoxaban; lipid-lowering agents Nilemdo/bempedoic acid and Nustendi/bempedoic acid plus ezetimibe) and oncology (Enhertu/trastuzumab deruxtecan for HER2-expressing cancers; Vanflyta/quizartinib for acute myeloid leukaemia). The portfolio is delivered as finished-dose formulations developed and manufactured through the parent group's global production network, including a major plant in Pfaffenhofen, Germany, with no UK-based manufacturing disclosed.

The business monetises through standard pharmaceutical commercialisation channels: field sales representatives engage NHS clinicians, pharmacists, primary care networks, and hospital trusts to drive prescribing, while formal collaborative and joint-working projects with named NHS organisations (FIND-AF atrial fibrillation detection, Capture AF, MDT Lipid Clinic optimisation, post-coronary re-vascularisation lipid services) aim to improve patient pathways in cardiovascular care. Pricing for prescription products is not publicly disclosed; access is mediated through NHS reimbursement and prescribing frameworks, with adverse-event reporting, medical information, and pharmacovigilance handled through dedicated UK contact channels.

As a wholly-owned subsidiary of a Tokyo-headquartered global group with more than 100 years of scientific heritage, a presence in over 20 countries, and roughly 2,500 European employees across 14 countries plus Canada, Daiichi Sankyo UK inherits the parent's R&D pipeline, regulatory filings, and brand equity while operating with UK-specific compliance, transparency (Disclosure UK), and ABPI Code of Practice alignment. Its headcount sits in the 251-500 range, and its go-to-market is enterprise field sales directed at NHS and private healthcare customers, supported by digital channels (corporate website, LinkedIn, X) and a parliamentary-level policy advocacy posture anchored by the 'Accelerating Ambition' programme.

Name

Daiichi Sankyo UK

Legal name

Daiichi Sankyo UK Ltd

Website

https://daiichi-sankyo.co.uk

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industry

Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)

Keywords

• Cardiovascular pharmaceuticals
• Oncology medicines
• Prescription drugs
• Anticoagulant therapy
• Lipid management

Headquarters

HQ city

Uxbridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Daiichi Sankyo UK generates revenue through the sale of prescription medicines to the NHS, healthcare providers, and pharmacies in the cardiovascular and oncology therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Daiichi Sankyo UK Ltd is the UK affiliate of the Japanese pharmaceutical group Daiichi Sankyo. It develops and supplies innovative prescription medicines in two principal therapeutic areas — cardiovascular disease (hypertension, anticoagulation, lipid management) and oncology (HER2-positive cancers, acute myeloid leukaemia). Products are marketed and distributed to the NHS, healthcare professionals, and pharmacies across the United Kingdom.

Product overview

Daiichi Sankyo UK is a pharmaceutical company that creates and supplies innovative prescription medicines. The company operates in two primary therapeutic areas: cardiovascular disease (including hypertension, hypercholesterolaemia, and anticoagulation) and oncology. The product portfolio consists of prescription-only medicines including Enhertu (oncology), Lixiana (anticoagulant), Nilemdo and Nustendi (lipid-lowering), and the Olmetec and Sevikar families of antihypertensive medications (including combination formulations with diuretics and calcium channel blockers), plus Vanflyta (oncology). These are marketed to NHS healthcare professionals and patients in the UK.

Differentiator

Problem solved

Functional benefit

Products and services

• Enhertu (trastuzumab deruxtecan) A prescription oncology medicine for the treatment of HER2-positive breast cancer and other HER2-expressing or HER2-mutant cancers, supplied to NHS hospitals and oncology specialists.
• Lixiana (edoxaban tosilate) An oral anticoagulant (Factor Xa inhibitor) prescribed to prevent and treat blood clots, including stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
• Nilemdo (bempedoic acid) A lipid-lowering prescription medicine used to treat hypercholesterolaemia in patients unable to tolerate statins or requiring additional LDL-cholesterol reduction.
• Nustendi (bempedoic acid, ezetimibe) A combination lipid-lowering prescription medicine containing bempedoic acid and ezetimibe for patients with hypercholesterolaemia requiring additional LDL-cholesterol lowering.
• Olmetec (olmesartan medoximil) An angiotensin II receptor blocker (ARB) prescribed for the treatment of essential hypertension.
• Olmetec Plus 20 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide) A combination antihypertensive prescription medicine pairing an ARB with a thiazide diuretic for the treatment of essential hypertension.
• Olmetec Plus 40 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide) A higher-dose combination antihypertensive prescription medicine pairing an ARB with a thiazide diuretic for the treatment of essential hypertension.
• Sevikar (olmesartan medoximil, amlodipine besilate) A combination antihypertensive prescription medicine pairing an ARB with a calcium channel blocker for the treatment of essential hypertension.
• Sevikar HCT (olmesartan medoximil, amlodipine besilate, hydrochlorothiazide) A triple-combination antihypertensive prescription medicine combining an ARB, a calcium channel blocker and a thiazide diuretic for the treatment of essential hypertension.
• Vanflyta 17.7 mg (quizartinib) A prescription oncology medicine for the treatment of acute myeloid leukaemia (AML), supplied to NHS hospitals and oncology specialists.
• Vanflyta 26.5 mg (quizartinib) A higher-dose prescription oncology medicine for the treatment of acute myeloid leukaemia (AML), supplied to NHS hospitals and oncology specialists.

Named customers13 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• IQVIA Operations France SASminorOthersIQVIA provides master and address data (name, title, company information, professional addresses, employment details, area of expertise and specialisation) to Daiichi Sankyo UK for obtaining relevant HCP contacts in business areas of interest and ensuring data quality.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• GSK UK: UK-headquartered major pharmaceutical company with cardiovascular and oncology specialty franchises; comparable NHS enterprise commercial operations.
• Roche UK: Major oncology competitor (HER2 franchise including Herceptin, Kadcyla, Phesgo) and broader UK specialty pharma presence; comparable NHS oncology engagement.
• Sanofi UK: Multinational pharma with cardiovascular (Praluent for lipid management) and specialty/oncology assets; comparable UK enterprise pharma commercial model.
• Novartis UK: Specialty pharma company with strong UK oncology franchise (Kisqali, Kymriah, radioligand therapy) and cardiovascular heritage; comparable scale and NHS engagement model.
• Bristol Myers Squibb UK: Direct competitor in DOAC anticoagulation via Eliquis (apixaban) and a strong oncology portfolio; comparable NHS-facing cardiovascular/oncology mix.
• Bayer UK: Multinational pharma operating in UK cardiovascular (anticoagulants Xarelto, hypertension franchise) and oncology; highly comparable product-level competition and NHS sales model.
• Boehringer Ingelheim UK: Direct DOAC competitor (Pradaxa/dabigatran) and cardiovascular franchise; comparable specialty pharma positioning in UK NHS.
• Pfizer UK: Major multinational pharma with significant UK cardiovascular and oncology presence; comparable specialty pharma portfolio and NHS enterprise sales model.
• AstraZeneca UK: UK-domiciled major pharmaceutical company with deep cardiovascular (e.g. Brilinta, Crestor legacy) and oncology (Enhertu's co-development partner) portfolios; directly comparable therapeutic-area mix and NHS-facing commercial model.

Broad incumbents

• Amgen UK: Specialty biotech with UK cardiovascular (Repatha for LDL-C lowering) and oncology presence; competes in adjacent cardiovascular and specialty spaces.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/DaiichiSankyoUK
• LinkedInlinkedin.com/company/daiichi-sankyo-uk-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daiichi Sankyo UK